| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Apr, 2026 |
| Sales | 0 | 0 | 0 | 650 | 0 |
| Sales Growth | unch | unch | -100.00% | unch | unch |
| Net Income | -99,960 | -98,330 | -66,390 | -59,280 | 0 |
| Net Income Growth | -1.66% | -48.11% | -11.99% | unch | unch |
Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lexeo Therapeutics is a clinical-stage genetic medicine company which defined cardiovascular diseases and APOE4-associated Alzheimer's disease are treated. Lexeo Therapeutics is based in New York City.
Fiscal Year End Date: 12/31